Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 3 | 9 |
| List of Tables | 7 | 3 |
| List of Figures | 10 | 2 |
| Anti-Inflammatory Therapeutics Market to 2017: Introduction | 12 | 2 |
| GBI Research Report Guidance | 13 | 1 |
| Anti-Inflammatory Therapeutics Market to 2017: Market Overview | 14 | 5 |
| Introduction | 14 | 1 |
| Revenue | 14 | 1 |
| Branded Vs Generics | 15 | 1 |
| Annual Cost of Treatment | 16 | 1 |
| Treatment Usage Pattern | 17 | 1 |
| Diseased Population | 18 | 1 |
| Treatment Seeking Population | 18 | 1 |
| Diagnosed Population | 18 | 1 |
| Prescription Population | 18 | 1 |
| Anti-Inflammatory Therapeutics Market to 2017: Geographical Landscape | 19 | 17 |
| Revenue Analysis by Geography | 19 | 2 |
| The US | 21 | 1 |
| Revenue | 21 | 1 |
| Annual Cost of Treatment | 22 | 1 |
| Treatment Usage Patterns | 23 | 1 |
| Diseased Population | 24 | 1 |
| Treatment Seeking Population | 24 | 1 |
| Diagnosis Population | 24 | 1 |
| Prescription Population | 25 | 1 |
| Top Five Countries of Europe | 25 | 1 |
| Revenue | 25 | 3 |
| Annual Cost of Treatment | 28 | 2 |
| Treatment Usage Patterns | 30 | 1 |
| Diseased Population | 31 | 1 |
| Treatment Seeking Population | 31 | 1 |
| Diagnosis Population | 31 | 1 |
| Prescription Population | 31 | 1 |
| Japan | 32 | 1 |
| Revenue | 32 | 1 |
| Annual Cost of Treatment | 33 | 1 |
| Treatment Usage Patterns | 34 | 1 |
| Diseased Population | 35 | 1 |
| Treatment Seeking Population | 35 | 1 |
| Diagnosis Population | 35 | 1 |
| Prescription Population | 35 | 1 |
| Anti-Inflammatory Therapeutics Market to 2017: Therapeutic Landscape | 36 | 63 |
| Respiratory Diseases | 36 | 1 |
| Introduction | 36 | 1 |
| Revenue | 36 | 2 |
| Revenue by Country | 38 | 1 |
| Branded vs. Generics | 39 | 1 |
| Annual Cost of Treatment | 40 | 1 |
| Treatment Usage Pattern | 41 | 1 |
| Diseased Population | 42 | 1 |
| Treatment Seeking Population | 42 | 1 |
| Diagnosed Population | 42 | 1 |
| Prescription Population | 42 | 1 |
| Drivers and Barriers the Respiratory Therapeutics Market | 43 | 1 |
| Drivers for Respiratory Therapeutics Market | 43 | 1 |
| Steady Increase in the Smoking Population | 43 | 1 |
| Stable Increase in Incidence Rates for Respiratory Diseases | 44 | 1 |
| Increase in Awareness Levels of Disease Progression and Etiology | 44 | 1 |
| Barriers for Respiratory Therapeutics Market | 44 | 1 |
| Patent Expirations and Entry of Generics Pose a Serious Problem for Primary Manufacturers | 44 | 1 |
| Reimbursement Restrictions on Drug Classes for Respiratory Diseases Restrict the Market Growth | 44 | 1 |
| Arthritis Therapeutics Market | 45 | 1 |
| Introduction | 45 | 1 |
| Revenue | 45 | 1 |
| Revenue by Country | 46 | 1 |
| Branded vs. Generics | 47 | 1 |
| Annual Cost of Treatment | 48 | 1 |
| Treatment Usage Pattern | 49 | 1 |
| Diseased Population | 50 | 1 |
| Treatment Seeking Population | 50 | 1 |
| Diagnosis Population | 50 | 1 |
| Prescription Population | 50 | 1 |
| Drivers and Barriers for Arthritis Therapeutics Market | 51 | 1 |
| Drivers for Arthritis Therapeutics Market | 51 | 1 |
| High Incidence and Prevalence Rate | 51 | 1 |
| Aging Population | 51 | 1 |
| Increasing Obese Population | 52 | 1 |
| Barriers for Arthritis Therapeutics Market | 52 | 1 |
| Low Patient Affordability | 52 | 1 |
| Availability of Alternative Non-Pharmacological Options | 52 | 1 |
| Low Treatment Seeking Rate | 52 | 1 |
| Multiple Sclerosis Therapeutics | 53 | 1 |
| Introduction | 53 | 2 |
| Revenue | 55 | 1 |
| Revenue by Country | 56 | 1 |
| Branded vs. Generics | 57 | 1 |
| Annual Cost of Treatment | 58 | 1 |
| Treatment Usage Pattern | 59 | 1 |
| Diseased Population | 60 | 1 |
| Treatment Seeking Population | 60 | 1 |
| Diagnosis Population | 60 | 1 |
| Prescription Population | 60 | 1 |
| Drivers and Barriers for Multiple Sclerosis Therapeutics Market | 61 | 1 |
| Drivers for Multiple Sclerosis Therapeutics Market | 61 | 1 |
| High Incidence and Prevalence Rate | 61 | 1 |
| High Prescription Rate | 61 | 1 |
| Launch of Several High-Priced Novel Disease-Modifying Therapies | 62 | 1 |
| Barriers for Multiple Sclerosis Therapeutics Market | 62 | 1 |
| Patient Affordability and Reimbursement Issues | 62 | 1 |
| Patent Expiry of Major Drugs is Expected to Cause a Decline in the Market | 62 | 1 |
| Lower Acceptability Regarding Use of the Medications | 62 | 1 |
| Psoriasis Therapeutics Market | 63 | 1 |
| Introduction | 63 | 1 |
| Revenue | 64 | 1 |
| Revenue by Country | 65 | 1 |
| Branded vs. Generics | 66 | 1 |
| Annual Cost of Treatment | 67 | 1 |
| Treatment Usage Pattern | 68 | 1 |
| Diseased Population | 69 | 1 |
| Treatment Seeking Population | 69 | 1 |
| Diagnosis Population | 69 | 1 |
| Prescription Population | 69 | 1 |
| Drivers and Barriers for Psoriasis Therapeutics Market | 70 | 1 |
| Drivers for Psoriasis Therapeutics Market | 70 | 1 |
| Growing Population | 70 | 1 |
| High Treatment Seeking Behavior | 70 | 1 |
| Increasing Rate of Prescription | 71 | 1 |
| Barriers for Psoriasis Therapeutics Market | 71 | 1 |
| Low Diagnosis Rate | 71 | 1 |
| Spondyloarthropathies Therapeutics Market | 71 | 1 |
| Introduction | 71 | 1 |
| Revenue | 72 | 1 |
| Revenue by Country | 73 | 1 |
| Branded vs. Generics | 74 | 2 |
| Treatment Usage Pattern | 76 | 1 |
| Diseased Population | 77 | 1 |
| Treatment Seeking Population | 77 | 1 |
| Diagnosis Population | 77 | 1 |
| Prescription Population | 77 | 1 |
| Drivers and Barriers for Spondyloarthropathies Therapeutics Market | 78 | 1 |
| Drivers for Spondyloarthropathies Therapeutics Market | 78 | 1 |
| Increase in Diseased Population | 78 | 1 |
| New Guidelines Issued to Bring Awareness to Spondyloarthropathies Patients | 78 | 1 |
| Barriers for Spondyloarthropathies Therapeutics Market | 79 | 1 |
| Low Diagnosis Rate | 79 | 1 |
| Inflammatory Bowel Disease | 79 | 1 |
| Introduction | 79 | 2 |
| Revenue | 81 | 1 |
| Revenue by Country | 82 | 1 |
| Branded vs. Generics | 83 | 1 |
| Annual Cost of Treatment | 84 | 1 |
| Treatment Usage Pattern | 85 | 1 |
| Diseased Population | 86 | 1 |
| Treatment Seeking Population | 86 | 1 |
| Diagnosis Population | 86 | 1 |
| Prescription Population | 86 | 1 |
| Drivers and Barriers for IBD Therapeutics Market | 87 | 1 |
| Drivers the IBD Therapeutics Market | 87 | 1 |
| Approval of Biologics | 87 | 1 |
| Significant Patient Population | 87 | 1 |
| Barriers for IBD Therapeutics Market | 88 | 1 |
| Diagnostic Limitations | 88 | 1 |
| Complex Etiology | 88 | 1 |
| Gout Therapeutics Market | 88 | 1 |
| Introduction | 88 | 3 |
| Revenue | 91 | 1 |
| Revenue by Country | 92 | 1 |
| Branded vs. Generics | 93 | 1 |
| Annual Cost of Treatment (ACT) | 94 | 1 |
| Treatment Usage Pattern | 95 | 1 |
| Diseased Population | 96 | 1 |
| Treatment Seeking Population | 96 | 1 |
| Diagnosed Population | 96 | 1 |
| Prescription Population | 96 | 1 |
| Drivers and Barriers for Gout Therapeutics Market | 97 | 1 |
| Drivers for Gout Therapeutics Market | 98 | 1 |
| Expected Launch of New Drugs will Drive the Gout Therapeutics Market | 98 | 1 |
| Limited Number of Approved Therapies will Create Concentrated Patient Pools | 98 | 1 |
| Increasing Prevalence and Diagnosis will Drive the Gout Therapeutics Market | 98 | 1 |
| Barriers for Gout Therapeutics Market | 98 | 1 |
| Lower Treatment Seeking Rate Could Prevent the Gout Therapeutics Market from Achieving Higher Growth | 98 | 1 |
| Low Patient Affordability for Biologics Could Affect the Growth in the Future | 98 | 1 |
| Anti-Inflammatory Therapeutics Market to 2017: Pipeline Analysis | 99 | 94 |
| Introduction | 99 | 2 |
| Anti-Inflammatory Therapeutics Market to 2017 Pipeline Assessment by Clinical Phase of Development | 101 | 1 |
| Filed Molecules | 101 | 1 |
| Phase III | 102 | 9 |
| Phase II | 111 | 25 |
| Phase I | 136 | 9 |
| Preclinical Phase | 145 | 28 |
| Discovery Phase | 173 | 5 |
| Anti-Inflammatory Therapeutics Market to 2017 Profiles of Promising Molecules | 178 | 1 |
| Indacaterol | 178 | 1 |
| Introduction | 178 | 1 |
| Mechanism of Action | 178 | 1 |
| Clinical Trial Management | 179 | 1 |
| BTR-15K | 179 | 1 |
| Introduction | 179 | 1 |
| Mechanism of Action | 179 | 1 |
| Clinical Trial Management | 179 | 1 |
| Flutiform | 180 | 1 |
| Introduction | 180 | 1 |
| Mechanism of Action | 180 | 1 |
| Clinical Trial Management | 180 | 1 |
| Iguratimod | 181 | 1 |
| Introduction | 181 | 1 |
| Mechanism of Action | 181 | 1 |
| Clinical Trial Management | 182 | 1 |
| OHR/AVR118 | 182 | 1 |
| Introduction | 182 | 1 |
| Mechanism of Action | 182 | 1 |
| Clinical Trial Management | 182 | 1 |
| Simponi | 183 | 1 |
| Introduction | 183 | 1 |
| Mechanism of Action | 183 | 1 |
| Clinical Trial Management | 183 | 1 |
| Zushima | 184 | 1 |
| Introduction | 184 | 1 |
| Mechanism of Action | 184 | 1 |
| Clinical Trial Management | 184 | 1 |
| Civanex | 184 | 1 |
| Introduction | 184 | 1 |
| Mechanism of Action | 185 | 1 |
| Clinical Trial Management | 185 | 1 |
| Naproxcinod | 185 | 1 |
| Introduction | 185 | 1 |
| Mechanism of Action | 185 | 1 |
| Clinical Trial Management | 186 | 1 |
| Gilenia | 187 | 1 |
| Introduction | 187 | 1 |
| Mechanism of Action | 187 | 1 |
| Clinical Trial Management | 187 | 1 |
| Cladribine | 187 | 1 |
| Introduction | 187 | 1 |
| Mechanism of Action | 187 | 1 |
| Clinical Trial Management | 188 | 1 |
| Fampyra | 189 | 1 |
| Introduction | 189 | 1 |
| Mechanism of Action | 189 | 1 |
| Clinical Trial Management | 189 | 1 |
| LAS41002 | 189 | 1 |
| Introduction | 189 | 1 |
| Mechanism of Action | 189 | 1 |
| Clinical Trial Management | 190 | 1 |
| BTR-15K | 190 | 1 |
| Introduction | 190 | 1 |
| Mechanism of Action | 190 | 1 |
| Clinical Trial Management | 190 | 1 |
| XOMA 052 | 191 | 1 |
| Introduction | 191 | 1 |
| Mechanism of Action | 191 | 1 |
| Clinical Trial Management | 191 | 2 |
| Anti-Inflammatory Therapeutics Market to 2017: Competitive Profiling | 193 | 11 |
| Abbott Laboratories | 193 | 1 |
| Company Overview | 193 | 1 |
| Marketed Products | 193 | 1 |
| SWOT Analysis | 193 | 1 |
| Amgen Inc. | 194 | 1 |
| Company Overview | 194 | 1 |
| Marketed Products | 194 | 1 |